Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial.
Daniel MrakDaniela SieghartElisabeth SimaderSelma TobudicHelga RadnerPeter MandlLisa GöschlMaximilian KoblischkeNikolaus HommerAngelika WagnerMargareta MayerLorenz SchubertLukas HartlKarin KozbialPhilipp HoferFelix KartnigThomas HummelAndreas KerschbaumerThomas DeimelAntonia PuchnerVenugopal GudipatiRenate ThalhammerPetra MundaKeziban Uyanik-ÜnalAndreas ZuckermannGottfried NovacekThomas ReibergerErika Garner-SpitzerRoman Reindl-SchwaighoferRenate KainStefan WinklerJosef S SmolenKarin StiasnyGottfried F FischerThomas PerkmannHelmuth HaslacherMarkus ZeitlingerUrsula WiedermannJudith H AberleDaniel AletahaLeonhard X HeinzMichael Markus BonelliPublished in: Nature communications (2022)
Impaired response to COVID-19 vaccination is of particular concern in immunosuppressed patients. To determine the best vaccination strategy for this vulnerable group we performed a single center, 1:1 randomized blinded clinical trial. Patients who failed to seroconvert upon two mRNA vaccinations (BNT162b2 or mRNA-1273) are randomized to receive either a third dose of the same mRNA or the vector vaccine ChAdOx1 nCoV-19. Primary endpoint is the difference in SARS-CoV-2 spike antibody seroconversion rate between vector and mRNA vaccinated patients four weeks after the third dose. Secondary outcomes include cellular immune responses. Seroconversion rates at week four are significantly higher in the mRNA (homologous vaccination, 15/24, 63%) as compared to the vector vaccine group (heterologous vaccination, 4/22, 18%). SARS-CoV-2-specific T-cell responses are reduced but could be increased after a third dose of either vector or mRNA vaccine. In a multivariable logistic regression analysis, patient age and vaccine type are associated with seroconversion. No serious adverse event is attributed to COVID-19 booster vaccination. Efficacy and safety data underline the importance of a booster vaccination and support the use of a homologous mRNA booster vaccination in immunosuppressed patients.Trial registration: EudraCT No.: 2021-002693-10.
Keyphrases
- sars cov
- end stage renal disease
- ejection fraction
- clinical trial
- newly diagnosed
- immune response
- chronic kidney disease
- prognostic factors
- randomized controlled trial
- binding protein
- peritoneal dialysis
- phase iii
- type diabetes
- phase ii
- dna damage
- machine learning
- dendritic cells
- adipose tissue
- toll like receptor
- patient reported outcomes
- saccharomyces cerevisiae